QU2 Cross-Cultural Psychometric Evaluation of the Ensemble MDS  by Bushnell, D.M. et al.
have covered various indications, mostly commonly psychiatric disorders (7 let-
ters), pain (5 letters), and cancer (4 letters). No DDMAC letter pertained to FDAMA
Section 114. CONCLUSIONS: The FDA continues to regulate health economic pro-
motions and express concern about certain inappropriate practices, particularly
unsupported work productivity claims and hidden clinical claims (i.e., about effec-
tiveness or safety) embedded in health economic information. More guidance from
the Agency would help clarify what level of substantiation is required for health
economic promotions.
PR2
THE IMPACT OF MINIMALLY INVASIVE SURGICAL TECHNOLOGY ON THE
COSTS OF EMPLOYEE ABSENTEEISM
Epstein AJ, Groeneveld PW, Harhay M, Yang F, Polsky D
University of Pennsylvania, Philadelphia, PA, USA
OBJECTIVES: To assess the impact of six minimally invasive surgical technologies
on worker absenteeism. METHODS: Using national health insurance claims data
(Thomson-Reuters MarketScan Commercial Database) andmatched data onwork-
place absence and short-term disability (MarketScan Health and Productivity Da-
tabase), we identified 37,495 patients aged 18-64 with employer-sponsored health
insurance who underwent either conventional or minimally invasive surgery dur-
ing 2001-2008 for ischemic heart disease (n18,184), uterine fibroids (n12,795),
prostate cancer (n3,466), peripheral vascular disease (n1,856), aortic aneurysms
(n245), or carotid disease (n949). Our primary endpoint was total days absent
from work, measured as the patient-specific difference between days absent dur-
ing the baseline period (-380 days to -15 days from procedure date) and the periop-
erative and post-operative periods (-14 days to  352 days) to account for individ-
ual-specific illness burden and propensity to use medical care. We studied the
similarly-constructed secondary endpoint of the inflation-adjusted sum of (a) the
dollar value of work absences (valued at $344/day for sick/vacation and $241/day
for short-term disability based on prior studies) and (b) the dollar value of health
plan expenditures for medical care. Propensity scores were constructed using year
of surgery, patient age, gender and Elixhauser comorbidities. RESULTS:Minimally
invasive surgerywas associatedwith fewer unadjusted days of workplace absence,
on average, for prostate cancer (-4.3 days), uterine fibroids (-11.4 days), peripheral
vascular disease (-11.9 days), aortic aneurysms (-20.2 days), and ischemic heart
disease (-26.0 days) (p0.001 for all comparisons). Absences were not significantly
different by surgical approach for carotid disease. The unadjusted sumof the dollar
value of absences and medical care spending was lower for minimally invasive
surgery for uterine fibroids (-$1,512, p0.01), aortic aneurysms (-$18,876, p0.06)
and heart disease (-$33,746, p0.001). Results were comparable after propensity
score adjustment. CONCLUSIONS: Minimally invasive procedures frequently re-
duce worker absenteeism by substantial amounts.
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QUALITATIVE ASSESSMENT OF HEALTH-RELATED PRODUCTIVITY
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Tundia NL1, Heaton PC1, Kelton CM2, Hass S3, Fuldeore M3
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OBJECTIVES: Assessment of lost productivity through health-related productivity
instruments (HRPIs) is useful for pharmacoeconomic research. The aim of this
study was to conduct a systematic review and critique of HRPIs. METHODS:
Through a comprehensive search in the PubMed database using the keywords
“health-related productivity,” “absenteeism,” and “presenteeism,” the following
generic, validatedHRPIswere found: American Productivity Audit andWorkHealth
Interview (APA&WHI), Endicott Work Productivity Scale (EWPS), Health and Labor
Questionnaire (HLQ), Health and Work Performance Questionnaire (HPQ), Health
and Work Questionnaire (HWQ), Health-Related Productivity Questionnaire-Diary
(HRPQ-D), Stanford Presenteeism Scale (SPS), Work Limitations Questionnaire
(WLQ), Work Productivity and Activity Impairment (WPAI), Work Productivity
Short Inventory (WPSI), and Worker Productivity Index (WPI). All HRPIs were
graded on five major and three minor assessment criteria. Major criteria included
(1) lost productivity could be attributed to a specific health-problem; (2) presentee-
ism was measured; (3) absenteeism was measured; (4) lost productivity was ex-
pressed in hours lost; and (5) productivity could be measured for both those in and
out of the labor force. Minor criteria included (1) how perceived impairment was
measured; (2) the minimum recall period required; and (3) whether population
norms existed or could be obtained. RESULTS: All of the HRPIs except HRPQ-D
failed to provide information on at least one major criterion. The SPS, WLQ, WPAI
and WPSI lacked information on 1 major criterion, APA&WHI, HLQ and HPQ on 2
major criteria, EWPS on 3major criteria and HWQ on 4major criteria. The HRPQ-D,
SPS, WLQ, WPAI and WPSI satisfied all or at least 1 major criterion but lacked 1-3
minor criteria. The common major criterion frequently lacking among the SPS,
WLQ, WPAI andWPSI was either household-related productivity loss or valuation.
CONCLUSIONS: Current HRPIs lack comprehensive estimation of lost productivity.
There is an opportunity to develop stronger survey instruments.
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BREAST CANCER MORTALITY RATES BY GEOGRAPHIC REGION, YEARS OF
POTENTIAL LIFE LOST, AND VALUE OF PRODUCTIVITY LOSSES AMONG
WOMEN AGED 20-49 YEARS IN THE UNITED STATES, 1970–2008
Ekwueme DU, Guy GP, Rim SH, Hall IJ, Thomas CC, Fairley TL, Rodriguez J, White A
Centers for Disease Control and Prevention, Atlanta, GA, USA
OBJECTIVES: There are no studies in the United States examining the trends in
mortality rates, years of potential life lost (YPLL), and value of productivity losses
due to breast cancer (BC) amongwomen aged 20-49 years.We examined the trends
in BCmortality rates by geographic region, estimated YPLL and value of productiv-
ity losses by race/ethnicity. METHODS: National mortality data from 1970-2008
were used to calculate age-adjusted mortality rates and rate ratios (RRs). Joinpoint
regression analysis was used to assess changes in trends over time. The YPLL were
calculated to quantify the burden of prematuremortality. The value of lost lifetime
productivity earnings of young women who died of BC in 2008 were used to quan-
tify the expected future value of lost productivity due to premature mortality.
RESULTS: From 1970 through 2008 the age-adjusted mortality rate from BC among
white youngwomenwas 11.45/100,000 and 17.97/100,000 among blacks. Compared
with whites, blacks had substantial higher age-adjusted breast cancer mortality
rates. BC mortality rates vary by geographic region. The decline in BC mortality
rates among blacks has been small (-0.68% per year) compared with whites (-2.02%
per year). During the same period, the total number of deaths associatedwith BC in
young women was 225,866, which accounted for an estimated 7.98 million YPLL.
The estimated total productivity losses attributed to BC in young women who died
in 2008 was $5.49 billion. On average, a young woman who died from BC in 2008
would lose $1.10 million in forgone lifetime earnings. CONCLUSIONS: Although
blacks have substantially higher age-adjusted BC mortality rates, there has been
very little overall change in death rates over time compared to other races. Our
results may implicate the need for focused attention to racial disparities in BC
diagnosis, treatment, and survivorship efforts among specific populations.
PODIUM SESSION III:
RESEARCH ON MEDICAL OUTCOMES QUESTIONNAIRES
QU1
THE DEVELOPMENT AND VALIDATION OF A REVISED VERSION OF THE
MEDICAL OUTCOMES STUDY SLEEP SCALE (MOS-SLEEP-R)
Yarlas AS, White MK, Smith KJ, Bjorner JB
QualityMetric Incorporated, Lincoln, RI, USA
OBJECTIVES: To develop a revised version of the Medical Outcomes Study Sleep
Scale (MOS-Sleep-R), and to evaluate its psychometric properties within a repre-
sentative sample of US adults. METHODS: The MOS-Sleep, developed in the late
1980s, is a 12-item patient-reported instrument measuring sleep outcomes over
the previous 4 weeks, yielding six domain scores – Disturbance, Adequacy, Som-
nolence, Snoring, Awakening to due to shortness of breath/headache, andQuantity
– and two global Sleep Problem Indices (SPI). The MOS-Sleep-R implemented the
following changes: the response option “a good bit of the time” was removed; a
1-week recall period formwas introduced; and 0-100 scores were replaced by stan-
dardized T-scores (mean50, standard deviation10 in the US general population)
with higher scores reflecting better sleep outcomes. Standardization was based on
data from a 2009 US internet-based general population survey. The psychometric
properties of both 1-week and 4-week recall forms of the MOS-Sleep-R were exam-
ined within this development sample. RESULTS: The 1-week and 4-week recall
forms of the MOS-Sleep-R were completed by 2045 and 2033 respondents, respec-
tively. The psychometric properties of the 1-week and 4-week forms were similar.
Patterns of inter-item and item-scale correlations support the scaling assumptions
of the instrument. All multi-item domains, global index scores, and the total scales
showed adequate internal consistency reliability (all Cronbach’s  0.75). Patterns
of correlations between MOS-Sleep-R scores with criterion measures of quality of
life, psychological state, and work and health outcomes indicated adequate con-
vergent validity. Differences in mean scores across groups that differed on the
criterion outcomes supported the instrument’s discriminant validity.
CONCLUSIONS: The MOS-Sleep-R introduces a number of improvements, includ-
ing simplified response sets, the introduction of a 1-week recall form, and norm-
based scoring that enhances interpretability of scores. Both the 1-week and 4-week
recall period forms of the MOS-Sleep-R demonstrated good reliability and validity.
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Bushnell DM1, Mccarrier KP2, Martin ML2, Paczkowski R3, Shen W3, Buesching D3
1Health Research Associates, Inc., Mountlake Terrace, WA, USA, 2Health Research Associates,
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OBJECTIVES: The ENSEMBLE MDS is a battery of phenotypic patient-reported in-
struments administered at baseline in clinical studies. The component measures
assess potential predictors (Self-Reported Health Status (SRH), Total Illness Burden
Index (TIBI), Patient Health Questionnaire-4, Depression Diagnosis, Perceived
Stress Scale) or effect modifying factors of clinical outcomes and/or treatment
response (MacArthur Perceived Status Ladder, MacArthur Income, Barratt Simpli-
fied Measure of Social Status, Perceived Social Support Scale (SS-5). This report
furthers the initial validation conducted in the United States by evaluating the
reproducibility and construct validity outside the United States. METHODS: The
ENSEMBLE MDS and other assessments (MOS SF-36, EQ-5D, Life Orientation Test-
Revised (LOT-R), items on illness/bed days and doctor visits) were administered to
a sample of adults with depression, type 2 diabetes, or rheumatoid arthritis in
Germany (n61), Spain (n61) and Singapore (n56, Simplified Chinese). Partici-
pants completed the battery on paper and returned one-week later to complete a
retest. Test-retest reproducibility was assessed using the intraclass correlation
coefficient (ICC); convergent validity by Pearson correlations between MDS instru-
ments and components of the SF-36 and EQ-5D, with hypothesized relationships
significant at r0.30; and known-groups tested using tertiles of the LOT-R, doctor
visits and illness days. RESULTS: The mean age of the participants was 5513
years, 63% were female, 66% were married/living with partner. Between 85% and
100% completed MDS instruments at the retest (mean 6.70.6 days). The ICCs for
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the retest of different components ranged from 0.81 to 0.99. All hypothesized cor-
relationswith convergentmeasureswere significant (r0.40; p0.01), and theMDS
SS-5 discriminated between LOT-R tertiles (F24.6, p0.001), SRH between doctor
visits (F8.0 p0.01) and TIBI between illness days (F14.9, p0.001).
CONCLUSIONS: Consistent with the results found in the United States, the ENSEM-
BLE MDS was observed to have adequate reproducibility, appropriate convergent
validity and to significantly discriminate between known groups outside the
United States.
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OBJECTIVES:Actinic keratosis is a highly prevalent epidermal neoplastic condition
among people in the United States with fair skin and a history of long term UV
exposure. A new self-assessment survey-based tool was developed to help people
assess their risk of either having or developing actinic keratosis. The objective of
this research was to assess detailed psychometrics of the developed survey.
METHODS: A test questionnaire, comprised of 10 items, was initially developed
using data obtained from subjects in routine clinical practice and interviews with
dermatologists. The instrument was administered along with established and val-
idated skin health assessment instruments (DLQI and Skindex-16) to 150 subjects
prior to them being given a diagnosis of actinic keratosis by the dermatologist. A
total of 75 subjects with a clinical diagnosis of actinic keratosis and 75 age/sex
matched controls without actinic keratosis formed the sample for this study. Ex-
ploratory factor analyses, item response theory analyses, and other psychometric
techniques were used to assess the reliability and validity of the Actinic Keratosis
Risk Questionnaire (AKRQ). RESULTS: The final AKRQ instrument assessed was
refined based on the results of exploratory factor analysis and item response tech-
niques, ultimately limiting the scale to six items. The resulting instrument had
good internal consistency (Chronbachs alpha  0.70) and correlations with other
validatedmeasures of skin quality of life (rho0.596with the Skindex-16 and rho
0.429 with the DLQI, P0.01). The sensitivity, specificity, positive and negative pre-
dictive values of the AKRQ was found to be 69.3%, 73.3%, 72.2% and 70.5%
respectively. CONCLUSIONS: The AKRQ is a reliable and valid tool whichmay help
patients self-assess their risk of either having or developing actinic keratosis based
on their skin health-related behavior and quality of life symptomatology.
QU4
ASSESSING THE VALIDITY AND RELIABILITY OF A PATIENT SATISFACTION
SURVEY FOR AN EMPLOYER-SPONSORED MEDICATION THERAPY
MANAGEMENT (MTM) PROGRAM
Majercak K, Pinto S, Bechtol R, Borse M
The University of Toledo, College of Pharmacy and Pharmaceutical Sciences, Toledo, OH, USA
OBJECTIVES: Patient satisfaction is a critical component of health care perfor-
mance in all settings including pharmacy-provided services. Our study aimed to
assess the validity and reliability of a newly developed survey used to evaluate
patient satisfaction of an employer-sponsored medication therapy management
(MTM) program provided in an independent pharmacy setting. METHODS: This
exploratory study used a cross-sectional design. The survey was developed using
three previous instruments and using input from practicing pharmacists. The in-
strument consisted of three sections (experience with the pharmacist, pharmacy,
and pharmacy staff). Face validity was assessed by a review panel of practicing
pharmacists and researchers. Final survey consisted of thirty-four items. A five-
point Likert scale (1  strongly disagree to 5  strongly agree) was used. Data was
collected over a one-year period and analyzed using SPSS v. 17.0. Construct validity
was assessed by an exploratory factor analysis using the principal components
method and a varimax rotation. Internal consistency reliability was tested using
Cronbach’s alpha. RESULTS: Factor analysis with varimax rotation (n 171) re-
sulted in five dimensions. Upon assessment, we labeled the factors as Experience
with the Pharmacist, Experience with the Pharmacy, Experience with the Phar-
macy Staff, Satisfaction of Pharmacy Care, and Prescription Promptness. The KMO
measure of sampling adequacy was .954. Experience with the pharmacist ac-
counted for 62.86% of the variance with the eigenvalue of 21.373. Cronbach’s alpha
for the five dimensions was found to be .977, .927, .975, .962, .868, respectively.
CONCLUSIONS: Results indicate the survey demonstrates validity and reliability.
With health care moving towards a more patient-centered approach and an in-
creasing need to have patients evaluate services provided, the instrument devel-
oped for this study could serve as a valuable tool. Pharmacists may utilize this tool
to assess their ownMTMprograms. However, additional testing in other pharmacy
settings is recommended for further assessment.
PODIUM SESSION III:
DRUG UTILIZATION & PRICING
UT1
THE IMPACT OF COMPARATIVE EFFECTIVENESS RESEARCH ON DRUG
UTILIZATION IN THE UNITED STATES
Doyle JJ, Sepulveda B
Quintiles Global Consulting, Hawthorne, NY, USA
OBJECTIVES: As Comparative Effectiveness Research (CER) gains a stronger foot-
hold in the US Healthcare systemwe turn our sights on the market implications of
conducting “real-world” studies of the effectiveness and safety of a clinical inter-
vention to guide evidence-based practice. Barriers to assimilation of CER in clinical
decision-making may be shaped by market factors such as coverage, reimburse-
ment, and generic availability. This analysis aims to determine what, if any,
changes in prescribing patterns might have been precipitated by the findings of
CER studies and examines the possible causes of such changes with respect to
differences in efficacy, safety and price.METHODS:We examined prescribing pat-
terns for drugs included in six Comparative Effectiveness Research (CER) studies
–one neuroscience, one diabetes and four cardiovascular – before and after publi-
cation. Our analysis separately tracked new and refill prescriptions for the same
number of quarterly intervals before and after publication of the studies analyzed,
ending with Q2 (June) 2011. Drug prescription volumes and average wholesale
prices (except where noted) were obtained using SDI Health’s Vector One National
Audit. Metrics were compared in the quarters before and after study publication.
Statistical significance was defined as p0.05. Analyses were performed using Mi-
crosoft Excel, two-tailed t-test. RESULTS: Drugs included in three of the six CER
studies- neuroscience, diabetes and cardiovascular- showed significant changes in
new, refill or total prescriptions of the drugs studies that were consistent with the
published findings (i.e. positive changes following positive findings).
CONCLUSIONS: Factors, in addition to the studies’ findings themselves, that could
have contributed to the observations include pricing of the drugs compared in the
studies and generic availability.We hypothesize that factors impacting adoption of
CER results in clinical practice include the number of patients enrolled and the
method of dissemination of results.
UT2
IMPACT OF 2009-2011 GLOBAL HEALTH CARE REFORMS ON PRICING, ACCESS
AND HEALTH OUTCOMES STRATEGY
Aggarwal S
Novel Health Strategies, Bethesda, MD, USA
OBJECTIVES: During 2009-2011 major health care reforms were proposed and im-
plemented in a number of nations, for example, Affordable Care Act in the United
States, AMNOG inGermany, HSPT in France, KVG in Switzerland andNHSproposed
reform in the UK. These reforms havemajor implications on pricing,market access
and HEOR strategy for drug and device products. METHODS: To understand the
implications of these trends, we analyzed 2009-2011 reform bills and proposed
changes worldwide. Additionally, we interviewed public and private payers, key
opinion leaders and payer-influencers to understand implications of these reforms
on drug and device manufacturers. Stakeholders ranked various data collection
methods on a scale of 1-10 (1-least important and 10-most important). RESULTS:
The global healthcare landscape is expected to undergo significant change during
2012-2016. In the United States, government will play increased role as a single
payer, especially with?Medicare, Medicaid and CHIP programs? which will cover
114 million Americans, at a cost of $784 billion. In Germany, AMNOG bill marked
the end of free drug pricing andwould lead to increased insurance premiums (now
15.5% of wages). In the United Kingdom, NHS has proposed to replace PCTs with
500-1000 GP-led consortia and use value-based pricing for expensive drugs and
devices. Randomized controlled trial, budget impactmodel and systematic reviews
—ranked highest (7.5-9.1) among payers. Overall, payers view that in the future,
health economic assessments would play critical role in pricing, coverage and
reimbursement of branded products. CONCLUSIONS: This analysis shows that
global health care landscape is expected to undergo significant change during 2012-
2016. Discussions with payers, KOLs and payer-influencers highlights increased
importance of HEOR data in the future.
UT3
FIRM- AND DRUG-SPECIFIC PATTERNS OF GENERIC DRUG PRICES EXPERIENCED
BY UNITED STATES MEDICAID PROGRAMS: 1991-2008
Berry EA1, Kelton CM2, Yu Y2, Guo JJ3, Bian B1, Heaton PC1
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OBJECTIVES: After the patent expires for a branded pharmaceutical, generic drug
companies generally sell bioequivalent versions of the drug, leading to lower
prices. Considering more drugs over a longer period of time than previously in the
literature, the objectiveswere to (1) describe the trends in branded and generic drug
prices post-entry; and (2) estimate the effects of drug, firm, and market character-
istics on branded and generic prices.METHODS: The primary data source was the
Medicaid State Drug Utilization Data maintained by the Centers for Medicare &
Medicaid Services. Quarterly utilization and expenditure data from 1991-2008were
extracted for 83 drugs that experienced initial generic entry between 1992 and 2004.
A relative price for a specific drug, firm, and quarter was constructed as Medicaid
reimbursement per unit divided by average reimbursement per unit of the branded
drug the year before entry. Autoregressive fixed-effects and random-effects mod-
els were estimated to explain relative drug price. RESULTS: For the 83 drugs, prices
for 229 firmswere followed from the first quarter of generic entry until 2008. Twelve
quarters after generic entry, 17% of drugs had average relative generic price less
than 50% of the original branded price. The number of firms had a statistically
significant (p0.01) negative effect on price. For each additional firm manufactur-
ing the generic drug, average price was estimated to fall by 8 percentage points.
Higher demand had a statistically significant (p0.01) positive effect. No statisti-
cally significant price premium for either early entry or firm size was found. Inject-
able drugs had prices that fell less (p0.01) than other drugs. CONCLUSIONS: Re-
sults are consistent with earlier studies showing that branded-drug prices rise and
generic drug prices fall as more generic firms enter. However, this fall is not as
strong for injectable drugs or for drugs with high demand.
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